<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392288</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6695</org_study_id>
    <secondary_id>XRP1526</secondary_id>
    <nct_id>NCT00392288</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.</brief_title>
  <official_title>A Multicenter, Multi-national, Randomized, Double-blind, Placebo-controlled, Study to Assess the Efficacy and Safety of Ciclesonide Metered-dose Inhaler (MDI) at 80 μg BID or 40 μg BID for 12 Weeks in Patients Aged 4 to &lt;12 Years With Persistent Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Primary objective: To demonstrate the efficacy of ciclesonide, compared to placebo, at 80 μg
      twice daily (BID) or 40 μg BID for 12 weeks in patients with persistent asthma.

      Secondary objective: To assess the safety and tolerability of ciclesonide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Week 12.</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change in FEV1 (Percent of predicted) from baseline to week 12. FEV1 was measured only in children between 6 to &lt;12 years only. Least Squares Mean were adjusted for Baseline FEV1, age [yrs], pooled center, previous corticosteroid therapy and holding chamber.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Daily Asthma Symptom Score at Week 12.</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change in total daily asthma symptom score from baseline to week 12. 5-Point, ordinal scale specifying patient's experience of symptoms during day and night from 0 (no symptoms) to 4 (symptoms that prevent the patient from engaging in daily activities or sleep)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Use of Albuterol/Salbutamol at Week 12.</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change in albuterol/salbutamol use from baseline to week 12</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">528</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo MDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciclesonide MDI 40 µg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciclesonide MDI 80 µg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide</intervention_name>
    <description>Ciclesonide MDI 40 µg BID over twelve weeks</description>
    <arm_group_label>Ciclesonide MDI 40 µg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide</intervention_name>
    <description>Ciclesonide MDI 80 µg BID over twelve weeks</description>
    <arm_group_label>Ciclesonide MDI 80 µg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo MDI over twelve weeks</description>
    <arm_group_label>Placebo MDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of persistent bronchial asthma for at least 3 months prior to screening;

          -  For patients with persistent bronchial asthma and being treated with a controller
             therapy: Documented use of an inhaled steroid or Singulair® 5mg once daily;

          -  For patients with persistent bronchial asthma and not being treated with controller
             therapy: Patients may have documented use of a reliever therapy such as
             albuterol/salbutamol or may be untreated;

          -  Morning Peak Expiratory Flow (AM PEF) of ≤90% of predicted values from the in-clinic
             spirometry after a 6 hour withhold of albuterol/salbutamol;

          -  Only patients aged between 6 to &lt;12 years must have a forced expiratory volume in one
             second (FEV1) of ≥50% to ≤85% of predicted normal after a 6 hour withhold of
             albuterol/salbutamol

        Exclusion Criteria:

          -  Nocturnal awakenings for asthma which require treatment with albuterol/salbutamol for
             4 or more nights out of the last 7 days of the screening period;

          -  Use of more than 8 puffs/day of albuterol/salbutamol on 3 or more consecutive days
             within the last 7

          -  Upper or lower respiratory tract infection within 4 weeks prior to screening and
             during screening period;

          -  History of life-threatening asthma, including a history of significant hypercarbia
             (pCO2 &gt;45 mmHg), prior intubation, respiratory arrest, or seizures as a result of an
             exacerbation of asthma;

          -  More than 3 in-patient hospitalization or emergency care visits due to asthma
             exacerbations in the year prior to screening;

          -  Use of injectable or oral corticosteroids within one month prior to screening, or more
             than 3 bursts) within 6 months prior to screening;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>sanofi-aventis, US</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Hungaria</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis Poland</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis South Africa</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2006</study_first_submitted>
  <study_first_submitted_qc>October 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2006</study_first_posted>
  <results_first_submitted>July 1, 2009</results_first_submitted>
  <results_first_submitted_qc>November 27, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2009</results_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchial Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Screening period 7-14 days, randomization with subsequent treatment period over 12 weeks</recruitment_details>
      <pre_assignment_details>The number of subjects in section Participant Flow is related to the number of randomized subjects (= subject who were eligible for treatment period). This number is different to the number of subjects of the Intention to Treat (ITT) population in Outcome Measures. The statistical analyses of the Outcome Measures is related to the ITT population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Metered Dose Inhaler (MDI)</title>
          <description>Placebo MDI over twelve weeks (ITT population)</description>
        </group>
        <group group_id="P2">
          <title>Ciclesonide MDI 40 µg BID</title>
          <description>Ciclesonide MDI 40 µg BID over twelve weeks (ITT population)</description>
        </group>
        <group group_id="P3">
          <title>Ciclesonide MDI 80 µg BID</title>
          <description>Ciclesonide MDI 80 µg BID over twelve weeks (ITT population)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="175">Number of randomized subjects is different to number of ITT population in Outcome Measures.</participants>
                <participants group_id="P2" count="177">Number of randomized subjects is different to number of ITT population in Outcome Measures.</participants>
                <participants group_id="P3" count="176">Number of randomized subjects is different to number of ITT population in Outcome Measures.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Period</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="143">ITT set = 163 patients</participants>
                <participants group_id="P2" count="155">ITT set = 166 patients</participants>
                <participants group_id="P3" count="159">ITT set = 172 patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent/legal guardian withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Metered Dose Inhaler (MDI)</title>
          <description>Placebo MDI over twelve weeks (ITT population)</description>
        </group>
        <group group_id="B2">
          <title>Ciclesonide MDI 40 µg BID</title>
          <description>Ciclesonide MDI 40 µg BID over twelve weeks (ITT population)</description>
        </group>
        <group group_id="B3">
          <title>Ciclesonide MDI 80 µg BID</title>
          <description>Ciclesonide MDI 80 µg BID over twelve weeks (ITT population)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="163"/>
            <count group_id="B2" value="166"/>
            <count group_id="B3" value="172"/>
            <count group_id="B4" value="501"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Aged 6 to &lt;12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aged 4 to &lt;6 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Week 12.</title>
        <description>Change in FEV1 (Percent of predicted) from baseline to week 12. FEV1 was measured only in children between 6 to &lt;12 years only. Least Squares Mean were adjusted for Baseline FEV1, age [yrs], pooled center, previous corticosteroid therapy and holding chamber.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Analyses are based on children of the ITT population. It includes all randomized patients who have a baseline and a valid post-randomization lung function measurement. The primary analysis was restricted to an age range between 6 and &lt;12 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Metered Dose Inhaler (MDI)</title>
            <description>Placebo MDI over twelve weeks (ITT population)</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide MDI 40 µg BID</title>
            <description>Ciclesonide MDI 40 µg BID over twelve weeks (ITT population)</description>
          </group>
          <group group_id="O3">
            <title>Ciclesonide MDI 80 µg BID</title>
            <description>Ciclesonide MDI 80 µg BID over twelve weeks (ITT population)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Week 12.</title>
          <description>Change in FEV1 (Percent of predicted) from baseline to week 12. FEV1 was measured only in children between 6 to &lt;12 years only. Least Squares Mean were adjusted for Baseline FEV1, age [yrs], pooled center, previous corticosteroid therapy and holding chamber.</description>
          <population>Analyses are based on children of the ITT population. It includes all randomized patients who have a baseline and a valid post-randomization lung function measurement. The primary analysis was restricted to an age range between 6 and &lt;12 years.</population>
          <units>Percent of predicted FEV1</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="1.06"/>
                    <measurement group_id="O2" value="5.3" spread="1.06"/>
                    <measurement group_id="O3" value="7.7" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is an analysis of the change from baseline to week 12 or last visit. In this pairwise comparison Ciclesonide was compared with Placebo by testing the average effect of Ciclesonide 40 and Ciclesonide 80 versus Placebo. As statistical test a t-test was used to compare the corresponding least-square means of both treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2696</p_value>
            <p_value_desc>Due to usage of a-priori ordered hypotheses, adjustment of p-values is not necessary. The pre-specified significance level was 0.05. The tests were carried out two-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model: Change in FEV1 = baseline FEV1 + age [yrs] + treatment + pooled center + previous corticosteroid therapy + holding chamber</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is an analysis of the change from baseline to week 12 or last visit. A t-test was used to compare the least-square means of Ciclesonide 80 versus Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0703</p_value>
            <p_value_desc>Due to usage of a-priori ordered hypotheses, adjustment of p-values is not necessary. The pre-specified significance level was 0.05. The tests were carried out two-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model: Change in FEV1 = baseline FEV1 + age [yrs] + treatment + pooled center + previous corticosteroid therapy + holding chamber</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an analysis of the change from baseline to week 12 or last visit. As statistical test a t-test was used to compare the corresponding least-square means of Ciclesonide 40 versus Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9146</p_value>
            <p_value_desc>Due to usage of a-priori ordered hypotheses, adjustment of p-values is not necessary. The pre-specified significance level was 0.05. The tests were carried out two-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model: Change in FEV1 = baseline FEV1 + age [yrs] + treatment + pooled center + previous corticosteroid therapy + holding chamber</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Daily Asthma Symptom Score at Week 12.</title>
        <description>Change in total daily asthma symptom score from baseline to week 12. 5-Point, ordinal scale specifying patient's experience of symptoms during day and night from 0 (no symptoms) to 4 (symptoms that prevent the patient from engaging in daily activities or sleep)</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Analyses are based on children of the ITT population. It includes all randomized patients who have a baseline and a valid post-randomization lung function measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Metered Dose Inhaler (MDI)</title>
            <description>Placebo MDI over twelve weeks (ITT population)</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide MDI 40 µg BID</title>
            <description>Ciclesonide MDI 40 µg BID over twelve weeks (ITT population)</description>
          </group>
          <group group_id="O3">
            <title>Ciclesonide MDI 80 µg BID</title>
            <description>Ciclesonide MDI 80 µg BID over twelve weeks (ITT population)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Daily Asthma Symptom Score at Week 12.</title>
          <description>Change in total daily asthma symptom score from baseline to week 12. 5-Point, ordinal scale specifying patient's experience of symptoms during day and night from 0 (no symptoms) to 4 (symptoms that prevent the patient from engaging in daily activities or sleep)</description>
          <population>Analyses are based on children of the ITT population. It includes all randomized patients who have a baseline and a valid post-randomization lung function measurement.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="0.08"/>
                    <measurement group_id="O2" value="-1.13" spread="0.08"/>
                    <measurement group_id="O3" value="-0.99" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Use of Albuterol/Salbutamol at Week 12.</title>
        <description>Change in albuterol/salbutamol use from baseline to week 12</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Analyses are based on children of the ITT population. It includes all randomized patients who have a baseline and a valid post-randomization lung function measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Metered Dose Inhaler (MDI)</title>
            <description>Placebo MDI over twelve weeks (ITT population)</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide MDI 40 µg BID</title>
            <description>Ciclesonide MDI 40 µg BID over twelve weeks (ITT population)</description>
          </group>
          <group group_id="O3">
            <title>Ciclesonide MDI 80 µg BID</title>
            <description>Ciclesonide MDI 80 µg BID over twelve weeks (ITT population)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Use of Albuterol/Salbutamol at Week 12.</title>
          <description>Change in albuterol/salbutamol use from baseline to week 12</description>
          <population>Analyses are based on children of the ITT population. It includes all randomized patients who have a baseline and a valid post-randomization lung function measurement.</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.08"/>
                    <measurement group_id="O2" value="-0.87" spread="0.08"/>
                    <measurement group_id="O3" value="-0.93" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The numbers of subjects at risk are based on the Safety Population. It was based on all randomized patients receiving at least one dose of the double-blind study medication after randomization.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Metered Dose Inhaler (MDI)</title>
          <description>Placebo MDI over twelve weeks (ITT population)</description>
        </group>
        <group group_id="E2">
          <title>Ciclesonide MDI 40 µg BID</title>
          <description>Ciclesonide MDI 40 µg BID over twelve weeks (ITT population)</description>
        </group>
        <group group_id="E3">
          <title>Ciclesonide MDI 80 µg BID</title>
          <description>Ciclesonide MDI 80 µg BID over twelve weeks (ITT population)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Electric shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="172"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="174"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="172"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="172"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="174"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="172"/>
                <counts group_id="E2" events="18" subjects_affected="12" subjects_at_risk="174"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="172"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="174"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca Clinical Study Information Center</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

